The University of Texas at Austin, 110 Inner Campus Drive, Austin, TX 78705, USA.
Morgan Welch Inflammatory Breast Cancer Research and Clinic Program, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA; Department of Medical Oncology, The National Cancer Institute, Cairo University, Cairo 11796, Egypt.
Surg Clin North Am. 2018 Aug;98(4):787-800. doi: 10.1016/j.suc.2018.03.009. Epub 2018 May 24.
Inflammatory breast cancer (IBC) is a rare form of breast cancer that accounts for only 2% to 4% of all breast cancer cases. Despite its low incidence, IBC contributes to 7% to 10% of breast cancer caused mortality. Despite ongoing international efforts to formulate better diagnosis, treatment, and research, the survival of patients with IBC has not been significantly improved, and there are no therapeutic agents that specifically target IBC to date. The authors present a comprehensive overview that aims to assess the present and new management strategies of IBC.
炎性乳腺癌（IBC）是一种罕见的乳腺癌，仅占所有乳腺癌病例的 2%至 4%。尽管发病率较低，但 IBC 导致的乳腺癌死亡病例占 7%至 10%。尽管国际上一直在努力制定更好的诊断、治疗和研究方案，但 IBC 患者的生存率并未得到显著改善，目前也没有专门针对 IBC 的治疗药物。作者提出了一个全面的综述，旨在评估 IBC 的现有和新的管理策略。
